CENTRAL HEALTH BOARD OF MANAGERS
APPLICANT CONTACT SHEET

Applicant Contact Information	
Name: Cynthia Curll Brinson, MD	
Spouse's Name: Tom Brinson	
Home Telephone # [redacted]	Cellular # (Optional) [redacted]
Email Address [redacted]	
Residential Home Address (No PO Box) 4 Green Lane Austin, Texas 78703	

Applicant Demographic Information			
Date of Birth: 04/24		Gender (Optional): Female	
County Commissioner Precinct:		Council District:	
☐ African-American	☐ Asian		☐ Hispanic
X- White	Other:		☐ Prefer Not To Indicate
Do you have a disability? ☐ Yes ☒ No			
Type (Optional)			
☐ Cognitive	☐ Hearing	☐ Mobility	☐ Visual
☐ Other			

How did you learn about this vacancy?		
☐ County website	☐ City website	☐ Facebook/Twitter
X Friend/Associate	☐ News Story	☐ Next Door
Professional/Civic Organization:		
Other:		

Call for Applications to the Central Health Board of Managers

The Travis County Commissioners Court and the City of Austin seek applications from qualified individuals to serve on the nine-member Board of Managers of Central Health. Four members of the Board are appointed by Travis County, four by the City of Austin, and a consensus candidate is jointly appointed by both entities. The joint appointee will serve for an unexpired term set to expire on December 31, 2020 as well an additional full-length term that will run from January 1, 2021 – December 31, 2024.

These nine appointees serve as the Board of Managers and organize, plan and supervise Central Health. The Commissioners Court approves the budget adopted by the Central Health Board of Managers and sets its associated tax rate. The Commissioners Court also retains broad oversight of the District's operations.

The District was created to improve healthcare delivery and access to underserved residents of Travis County and is intended to promote transparency and accountability to the public in the provision of health care. Information regarding the District's calendar, scheduled meetings and minutes of past meetings is available at http://www.centralhealth.net/meetings.html.

The minimum time commitment required is 10 – 15 hours per month but may exceed that due to other events in which Managers are asked to participate. Most meetings are held in the evening, although Central Health and community-related events may be equally divided between daytime and evening hours. In addition to service on the Board, Managers will be assigned to subcommittees.

Experience as a health care provider is not a necessary requirement for service, but understanding of the current health care system and a commitment to improving the patient experience is preferred.

The City of Austin and Travis County are seeking the following qualifications:

- Senior management-level experience in a non-governmental entity
- Experience serving on Boards of Directors for high-level businesses or for-profit organizations
- Demonstrated leadership experience requiring strategic planning, execution, and maintenance of successful business operations
- Understanding of risk models, insurance, or other complex financial information
- Knowledge of the issues and components related to the "safety net" health system
- Understanding of public health care delivery systems as well as finance and funding streams
- Reflective of the diversity of the communities served by Central Health
- Interest in serving the community, especially the low-income people who need health care in Travis County
- Recognition of Central Health's fiduciary responsibility to taxpayers
- Commitment to the mission, vision, and values of both Central Health and the Travis County Commissioners Court

Applicants must be a resident of Travis County.

CENTRAL HEALTH BOARD OF MANAGERS APPLICATION

Applicant Name
Cynthia Curll Brinson, MD

Education/Training History	
High School or equivalent (G.E.D.)	
Highland Park High School, Dallas, Texas	
Undergraduate School: University of Texas at Austin	
Degree:	Bachelor of Fine Arts
Graduate School: Texas Tech University Health Science Center, Lubbuck, Texas	
Degree:	Doctorate of Medicine
Licenses/Certifications: State of Texas Medical License 1991, American Board of Family Practice, ICH/Good Clinical Practices, NIH/Human Participant Protections Education	

Current Employment Information	
Name	Central Texas Clinical Research/Red River Family Practice
Work #	[redacted]
Email	[redacted]
Address 900 East 30th Suite 302, Suite 300 Austin Texas, 78705	

Most Recent Past Employment and Career Experience (include a separate detailed resume.)	
Employer	See Resume
Job Title	

Other Highlights
I have worked as the special needs Physician at the Travis County Jail, 1998 until the present.

I was Faculty and Program Director for the Family Medicine Residency Program, 1993-1998

I was a part time physician at the David Powell Clinic from 1991-1994, and again from 2010 or so until 2015

Current Professional Memberships and Business Achievement

Founding Physician for the KIND Clinic, which began as The HIV Prep Project in 2015 and became the KIND Clinic in 2017. The Kind Clinic is a not for profit sexual health clinic which provides: PREP to individuals at risk of acquiring HIV, HIV Care for HIV positive patients, testing and treatment of STD's and Gender Affirming Hormones, all at no cost to our patients.

Public Service (Include participation in local, state, and federal governmental processes.)

As Above.

Civic Participation And Community Leadership Roles

As above.
Adjunct Faculty at University of Texas Nursing School, 2000 to the present

Health and Human Services Experience and/or Knowledge

I have worked with the underserved population since my residency here in Austin:
I am the Special Needs Physician for the Travis County Corrections Complex, 1998-present
I have been Faculty and then Program Director for the Family Medicine Residency Program in Austin from 1994-1998.
I have worked at people's as a resident. I have worked at the STD clinic as a resident

I was the first physician to work the night clinic of the David Powell Clinic, and subsequently worked and scheduled the residents to cover this public Health Clinic from 1991-1995
I worked as a part time physician for the David Powell Clinic from 2004 -2013

Skills and Experience

☐ Administration Management	☐ Event Planning	X Medical
☐ Behavioral Health	☐ Finance/Budget	☐ Operations
☐ Business and Tax	☐ Government	☐ Philanthropy/Fund Raising
☐ Chemical Dependency/Addiction	☐ Human Resources	☐ Public Health
☐ Community Advocacy	☐ Legal	☐ Public Relations
X Education	☐ Marketing	☐ Writing/Communication

Statement of Purpose

In 150 words or less briefly summarize why you are seeking this judicial appointment.

I am an advocate for the medically under- represented and underserved populations in Austin. I am a fierce advocate for destigmatizing disease, and the people who suffer from these diseases. I do this by working tirelessly in the medical field for patient rights to receive fair and unbiased medical care.
Having worked with, and in, the systems of medical delivery in Austin, I am aware of the burdens patients, their families and their caregivers have in receiving adequate, timely, thoughtful care. I have attempted to demonstrate while teaching, that involving oneself directly by asking and understanding their personal limitations financially, physically, mentally, will benefit the patient, not just as a sympathetic supporter, but by streamline the care they receive. I have walked both sides of the medical street since my career began. I have taken care of the well insured and the noninsured, the rich and the poor. I have a good knowledge base of what is available in our community. I also have an understanding of some of what we are lacking in providing good, timely, financially responsible medical care.

I am a realist and frugal, especially in my work life. I am a relentless objector of inequalities and a kind and understanding supporter of those who are striving to solve difficult problems. I am opinionated, frank, outspoken, fierce, open-minded, and an optimist. If I can't move the mountain, I will go under, on top of, or around it. I do not take no for an answer, I do not easily give up or accept the status quo. I am a pain in the neck and a leader.

Maybe I can see things on this Board in a different way.
I believe that a small group of determined citizens can dramatically improve the community in which they live.

NOTE: PLEASE ATTACH A RÉSUMÉ.

CENTRAL HEALTH BOARD OF MANAGERS
CERTIFICATION OF APPLICANT

I hereby certify that the foregoing and any attached statements are true, accurate and complete. I agree that any misstatement, misrepresentation, or omission of a fact may result in my disqualification for appointment. I assign and hereby give Travis County and the City of Austin full authority to conduct background investigations pertinent to this application.

I agree to file the attached affidavit of eligibility prior to being considered for an appointment by Travis County of the City of Austin. I further agree to file an amendment in the event my status should change during the tenure of my appointment.

Cynthia C. Brinson, MD

Printed Name



Applicant's Signature

5/22/2020, this is a "copy" of application turned in 3/5/2020

Date

Please submit completed application and attachments to either:

IGR@traviscountytx.gov or Stephanie.Hall@austintexas.gov

APPLICATIONS RECEIVED AFTER THE DEADLINE WILL NOT BE ELIGIBLE FOR CONSIDERATION.

CENTRAL HEALTH BOARD OF MANAGERS
CONFLICT OF INTEREST DISCLOSURE AFFIDAVIT

STATE OF TEXAS §
COUNTY OF TRAVIS §

On this day, _Cynthia C Brinson, MD appeared before me, the undersigned notary public, and after I administered an oath, upon his/her oath, he/she said:

"My name is __Dr Cynthia Brinson. I am competent to make this affidavit. The responses to the questions stated in this affidavit are within my personal knowledge and are true and correct. In this affidavit, "Central Health" means the Travis County Hospital District d/b/a Central Health and "Board" means the Board of Managers of Central Health. I am making this affidavit to disclose potential conflicts of interest that might affect my ability to serve on the Board and to verify that I meet all eligibility requirements for appointment to the Board.

"I understand that providing no information in the space provided in items 4 through 25 is a statement that these circumstances do not apply to either my spouse or me as applicable and I affirm that all of the following statements are true and correct.

1. I reside in Travis County, Texas.

EMPLOYMENT

2. I am not an elected official.

3. My **spouse's** employer is __Retired/Disabled.

   My **spouse** works in _____ (department).

   My **spouse's** position title is _____.

FINANCIAL RELATIONSHIPS N/A

4. If my employer has, or is expected to have, a financial relationship (other than as a taxpayer) with any of the following entities, I have marked an X in the box preceding the entity:

☐ Central Health
☐ City of Austin
☐ Travis County
☐ Ascension Health
☐ Austin Independent School District
☐ Central Texas Community Health Centers (d/b/a CommUnityCare)
☐ Community Care Collaborative (CCC)
☐ Foundation Communities
☐ Health Alliance for Austin Musicians (HAAM)
☐ Hospital Corporation of America (HCA)
☐ Husch Blackwell
☐ Huston-Tillotson University
☐ Integral Care (ATCIC)
☐ Lone Star Circle of Care
☐ People's Community Clinic
☐ Planned Parenthood of Greater Texas
☐ Sendero Health Plans

☐ Seton Healthcare Family
☐ SIMS Foundation
☐ St. David's HealthCare
☐ The University of Texas at Austin
☐ United Way Greater Austin
☐ University of Texas System
☐ Another entity, not listed

If you selected any of the above entities, please state your financial relationship. If you selected another entity, not listed, please include the entity name: N/A

5. If my spouse's employer has, or is expected to have, a financial relationship (other than as a taxpayer) with any of the following entities, I have marked an X in the box preceding the entity:

☐ Central Health
☐ City of Austin
☐ Travis County
☐ Ascension Health
☐ Austin Independent School District
☐ Central Texas Community Health Centers (d/b/a CommUnityCare)
☐ Community Care Collaborative (CCC)
☐ Foundation Communities
☐ Health Alliance for Austin Musicians (HAAM)
☐ Hospital Corporation of America (HCA)
☐ Husch Blackwell
☐ Huston-Tillotson University
☐ Integral Care (ATCIC)
☐ Lone Star Circle of Care
☐ People's Community Clinic
☐ Planned Parenthood of Greater Texas
☐ Sendero Health Plans
☐ Seton Healthcare Family
☐ SIMS Foundation
☐ St. David's HealthCare
☐ The University of Texas at Austin
☐ United Way Greater Austin
☐ University of Texas System
☐ Another entity, not listed

If you selected any of the above entities, please state your financial relationship. If you selected another entity, not listed, please include the entity name: N/A

6. If I intend to seek a business arrangement with Central Health, the type of business is stated below:

N/A

7. If my **spouse** intends to seek a business arrangement with Central Health, the type of business is stated below:

N/A

8. If I do work for or participate in the management of any organization (other than a political subdivision) that receives funds from Travis County or the City of Austin or is expected to receive funds from Central Health, the name of the organization, the entity providing funds and the type of funding are stated below:

N/A

9. If my **spouse** does work for or participates in the management of any organization (other than a political subdivision) that receives funds from Travis County or the City of Austin or is expected to receive funds from Central Health, the name of the organization, the entity providing funds and the type of funding are stated below:

N/A

INDEPENDENCE

10. If I am employed or engaged in a business or professional activity that might cause me to disclose confidential information acquired as a result of my being a member of the Board, the name of the business or activity is stated below:

N/A

11. If my **spouse** is employed or engaged in a business or professional activity that might cause me to disclose confidential information acquired as a result of my being a member of the Board, the name of the business or activity is stated below:

N/A

12. If I am employed or engaged in any activity that could significantly impair my independence of judgment in the performance of my official duties as a member of the Board, the name of the activity is stated below:

N/A

13. If my **spouse** is employed or engaged in any activity that could significantly impair my independence of judgment in the performance of my official duties as a member of the Board, the name of the activity is stated below:

14. If I own an interest in real property that is expected to be acquired for a Central Health project, the location of the property is stated below:

N/A

15. If my **spouse** or **minor children** own an interest in real property that is expected to be acquired for a Central Health project, the location of the property is stated below:

N/A

16. If I have material personal investments that could create a conflict between my private interests and the interests of Central Health, the type and extent of those investments is stated below:

N/A

17. If my **spouse** or **minor children** have material personal investments that could create a conflict between their private interests and the interests of Central Health, the type and extent of those investments is stated below:

N/A

18. If I own or control, either directly or indirectly, more than 10% of the stock or shares of a company that receives funds from Travis County or the City of Austin or is expected to receive funds from Central Health, the name and percentage of ownership of those companies are stated below:

N/A

19. If my **spouse** or **minor children** own or control, either directly or indirectly, more than 10% of the stock or shares of a company that receives funds from Travis County or the City of Austin or is expected to receive funds from Central Health, the name and percentage of ownership of those companies are stated below:

N/A

03 N/A

20. If I use or receive a substantial quantity of goods or services from Travis County or the City of Austin, or expect to receive a substantial quantity of goods or services from Central Health, the type and approximate annual quantity are stated below:

N/A

21. If my **spouse** or **minor children** use or receive a substantial quantity of goods or services from Travis County or the City of Austin, or expect to receive a substantial quantity of goods or services from Central Health, the type and approximate annual quantity are stated below:

N/A

LOBBYING AND CONSULTING

22. If I am an owner, officer, employee, manager or paid consultant of any association either involved in the field of health care services or supplies, or lobbying for health care services, my position and the name of the association are stated below:

N/A

23. If my **spouse** is an owner, officer, employee, manager or paid consultant of any association either involved in the field of health care services or supplies, or lobbying for health care services, my position and the name of the association are stated below:

N/A

24. If, currently or during the last three years, I am or was a lobbyist for compensation at or on behalf of Travis County or the City of Austin, my activities and on whose behalf they were provided are stated below:

N/A

25. If, currently or during the last three years, my **spouse** is or was a lobbyist for compensation at or on behalf of Travis County or the City of Austin, my **spouse**'s activities and on whose behalf they were provided are stated below:"

N/A

Signature

Printed Name: Cynthia C Brinson, MD

SWORN TO and SUBSCRIBED before me by Dr Brinson on 5/22/ 2020.

DANIEL L. DUNCAN
Notary Public, State of Texas
Comm. Expires 09-23-2023
Notary ID 130379516

Daniel L. Duncan
Notary Public in and for the State of Texas

Professional Experience:

Current:

Medical Director
Central Texas Clinical Research, LLC
900 East 30th Street, Suite 302
Austin, Texas 78705
1999 – Present

Private Physician
Red River Family Practice
900 East 30th, Suite 300
Austin, Texas 78705
1999 – Present

HIV and Chronic Care Physician
Travis County Correctional Facility
3614 Bill Price Rd
Dell Valle, Texas 78617
1999 – Present

Adjunct Clinical Affiliate
University of Texas School of Nursing
1710 Red River
Austin, Texas 78701
2003 – Present

National Speaker for Gilead Sciences
2008 – Present

Chief Medical Officer/ Board Member
Texas Health Action/Kind Clinic
8140 N. Mopac Expressway
Austin, Texas 78759
2017 – Present

National Speaker for ViiV Healthcare
2019 – Present

Past:

Medical Director/Board Member
Austin PrEP Access Project
900 E. 30th Street, Suite 302
Austin, Texas 78705
2015 - 2017

Part Time Faculty Physician - Contract
Seton Family Practice Residency Program
Southwestern Medical Schools
1313 Red River St #100
Austin, Texas 78701
2013 – 2015

Part-Time Physician
David Powell Clinic
4614 N. IH-35
Austin, Texas 78751
2004 - 2013

Program Director, Central Texas Medical Foundation
Family Practice Residency Program
4614 North IH 35
Austin, Texas 78751
1996 - 1999

Medical Director, Faculty Clinic
1313 Red River, Suite 220
Austin, Texas
1997- 1999

Investigator, Central Texas Medical Foundation
HIV Study Group
1992 - 1999

Education:

Undergraduate:
University of Texas at Austin, BA 1985

Medical:
Texas Tech University, Health Science Center Lubbock, Texas,
M.D., 1990

Residency:

Family Practice Residency Program of Central Texas Medical Foundation, Brackenridge Hospital
Austin, Texas, 1990-1993

Chief Resident, Family Practice Residency Program of Central Texas Medical Foundation, 1992-1993

Fellowship:

Academic and Research Development, McLennan County Medical Education Research Foundation, 1993-1994

Honors:

Byron E Cox Spirit of Caring Award, 2013
Weinberg Award for Teaching, 1994
Best Doctors! Austin, Tx 2002, 2004, 2007, 2009, 2011, 2014, 2017
Austin Pride-Grand Marshall-2016
The POZ 100, 2017
John P. McGovern Champion of Health Award, 2018
Texas Academy of Family Physicians Prevenative Health Award, 2020
HIV Planning Council Professional Star Award Nominee 2019
Human Rights Campaign Bettie Naylor Visibility Award 2020

Practice Experience:

Director, Central Texas Medical Foundation Family Practice Residency Program, Austin, TX 1995

Associate Director, Central Texas Medical Foundation Family Practice Residency Program, Austin, Texas, 1994-1995

Faculty Member, Central Texas Medical Foundation, Family Practice Residency Program, Austin, Texas, 1993-1995

Board Certification:

American Board of Family Practice, 1993
Recertified 2000, 2007, 2014

Medical Licensure:

State of Texas 1991 – License Number H9819

Membership:

Texas Medical Association
Texas Association of Family Practice
American Association of Family Practice
American Academy of Family Physicians
American Medical Association
Travis County Medical Society
American Academy of HIV Medicine, HIV Specialist 2008

Training/Certifications:

ICH/Good Clinical Practices
NIH/Human Participant Protections Education

Advisory Board:

National Advisory Board Gilead Sciences 2013 – Present
Regional Advirsory Board Bristol Meyers Squibb 2014 – Present

Education Board:

National Educational Board Gilead Sciences 2013 – 2017

Presentations:

2020 Conference on Retroviruses and Opportunistic Infections
"SAFETY AND ANALYTIC TREATMENT INTERRUTION OUTCOMES OF VESATOLIMOD IN HIV CONTROLLERS" Devi SenGupta[1], Moti Ramgopal[2], Cynthia Brinson[3], Edwin DeJesus[4], Anthony Mills[5], Peter Shalit[5], Scott McCallister[1], Hiba Graham[1], Heena Patel[1], Lijie Zhong[1], Joseph Hesselgesser[1], Brian Doehle[1], Susan Guo[1], Diana Brainard[1], Steven G. Deeks[6] **March 10th in Boston, Massachusetts**

9th International Workshop on HIV & Women
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in Women: Pooled Analysis of 7 Clinical Trials- Melanie A. Thompson, Indira Brar, Cynthia Brinson, Catherine M. Creticos, Debbie Hagins, Ellen Koenig, Claudia T. Martorell, Cristina Mussini, Laura Waters, Susan Guo, Ya-Pei Liu, Lauren Temme, Devi SenGupta, Moupali Das- **March 2nd**, in Seattle, Washington

2019 Conference on Retroviruses and Opportunistic Infections (CROI)
96 WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT-NAÏVE ADULTS AND ADULTS ≥50 YRS" ID2586- Samir K. Gupta[1], Anthony Mills[2], Cynthia Brinson[3], Kimberly Workowski[4], Amanda Clarke[5], Andrea Antinori[6], Jeffrey L. Stephens[7], Ellen Koenig[8], Jose R. Arribas[9], David M. Asmuth[10], Douglas Ward[11], Jürgen K. Rockstroh[12], Mingjin Yan[13], Diana Brainard[13], Hal Martin[13] –**March 4th-7th**, in Seattle, Washington

ID Week- Poster Presentation
A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs ABC/DTG/3TC in Treatment-Naïve Adults at Week 96- David Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie A. Thompson, Cynthia Brinson, Debbie Hagins, Moti N. Ramgopal, Andrea Antinori, Xuelian Wei, Kirsten White, Sean Collins, Andrew Cheng, Hal Martin
October 3-7, 2018 in San Francisco, CA

TexMed 2018, TMA's Annual Session
Presentation on "Population Health in Your Practice" Assessing Patients for Prevention. How to take a Sexual History to Create a LGBT-friendly Office-**19-May 2018,** in San Antonio, Texas

22nd International AIDS Conference
Cardiovascular Disease Risk Assessments and Fasting Lipid Changes in Virologically Suppressed Patients Randomized to Switch to Tenofovir Alafenamide versus Continuing Tenofovir Disoproxil Fumarate- C. Orkin, F.Castelli, Y.Yazdanpanah, J. Rockstroh, C.Brinson, G.Diperri, Y.-P.Liu, L. Zhong, S.E. Collins, H.Martin, D. Sengupta, M. Das- **23-27 July 2018,** Amsterdam, Netherlands

2017 Conference on Retroviruses and Opportunistic Infections (CROI)
Phase III Sword 1&2: Switch to DTG+RPV maintains virologic suppression through 48 wks (ID 2421), - Josep M. Llibre[1], Chien-Ching Hung[2], Cynthia Brinson[3], Francesco Castelli[4], Pierre-Marie Girard[5], Lesley

Kahl[6], Elizabeth Blair[7], Brian Wynn[8], Kati Vandermeulen[9], Michael Aboud[10]- **February 13-16, 2017,** in Seattle, Washington

7th International Workshop on HIV & Aging-2016-Poster Presentation
Week 96 Efficacy and Safety of Tenofovir Alafenamide(TAF) vs Tenofovir Disoproxil Fumarate(TDF) in Older, HIV-Infected Treatment-Naïve Adults : D. Ward, C. Brinson- **September 26- 27, 2016**, in Washington, D.C.

Fumarate(TDF) in Older, HIV-Infected Virologically-Suppressed Adults: D. Goldstein, C. Brinson- **September 26- 27, 2016**, in Washington, D.C.

18th International Workshop on Co-mOrbidities and Adverse Drug Reactions in HIV-Poster Presentation
Common Adverse Drug Reactions of Elvitegravir, Cobicistat, and Emtricitabine Co-formulated with Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate: S Segal-Maurer, K Henry, C. Brinson, G. Crofoot, P Esser, T Nguyen-Cleary, M Dass, S McCallister-**September 12th, 2016,** New York, New York

7th Deutsch Osterreichischer AIDS-Kongress DOAK-2015-Poster Presentation
Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis: J Lalezari, GH Latiff, C Brinson, J Echevarría, S Treviño-Pérez, JR Bogner, D Stock7, SR Joshi, GJ Hanna, M Lataillade- **June 24-27, 2015,** Dusseldorf, Germany

22nd Conference on Retroviruses and Opportunistic Infections – Poster Presentation
Cabotegravir and Rilpivirine As 2-Drug Oral Maintenance Therapy: LATTE W96 Results. D. Margolis, C. Brinson, G. H. Smith, J. De Vente, D. Hagins, S. K. Griffith, M. St Clair. **February 23-26, 2015**, Seattle, WA, USA 2015

ID Week- Poster Presentation

Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced

Subjects: Week 24 Analysis: J Lalezari, GH Latiff, C Brinson, J Echevarría, S Treviño-Pérez, JR Bogner,

D Stock, SR Joshi, GJ Hanna, M Lataillade- **October 8-12, 2014**, Philadelphia, PA. USA

ACTHIV Conference –Poster Presentation
Intelence aNd pRezista Once A Day Study (INROADS): A Multicenter, Single-Arm, Open-Label Study of Once Daily Combination of Etravirine (ETR) and Darunavir/Ritonavir (DRV/r) as Dual Therapy in Early Treatment-Experienced Subjects. P. Ruane, C. Brinson, P. Kumar, E. DeJesus, A. Shprecher, R. Ryan, M. Cho, D. Anderson. **May 8-10, 2014**, Denver, CO, US

4th International Workshop on HIV and Women from Adolescence through Menopause- Poster Presentaion
STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF is
Safe and Well-Tolerated with Efficacy Comparable to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96- Creticos, C., McDonald, C, Segal-Maurer S; Brar I; Wade B; Brinson, C;

Garner W; Porter D; Fralich T; DeMorin J; Lugo-Torres O ; Elbert, E. **January 13-14, 2014**, Washington, DC, USA

53rd Interscience Conference on Antimicbrobial Agents and Chemotherapy – Poster Presentation
STaR: Virologic Outcomes and Safety in ART-Naïve Adult Females for Single-Tablet Regimen Rilpivirines/Emtricitabine/Tenofovir DF Compared to Efavirenz/Emtricitabine/Tonofovir DF at Week 48. C. Brinson, S. Segal-Maurer, I. Brar, C. Creticos, C. McDonald, B. Wade, R. Ebrahimi, D. Porter, S. De-Oertel, T. Fralich, J. DeMorin, K. Khorana **September 10-13, 2013, Denver, CO, USA**

20th Conference on Retroviruses and Opportunistic Infections- Poster Presentation
Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naïve HIV Infected Individuals. Cynthia Brinson, Author, S.Walmsley, K. Arasteh, M .Gorgolas, L. Schneider, C. Brennan, K. Pappa, S. Almond, C. Grainier, F. Raffi. **March 3-6,2013; Atlanta, GA, USA**

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in HIV Positive Adults With Prior 23-valent Pneumococcal Polysaccharide Vaccination. Cynthia Brinson, Co-Author, M.Glesby, R. Greenberg, J. Lalezari, D. Scott, B. Schmoele-Thoma, A. Gurtman, R. Natuk, M. Patton, W. Watson.,CRO1, **March 3-6, 2013; Atlanta, GA, USA**

Tenth International Conference on AIDS - Poster Presentation
Comparison of Cervical Cytology with Colposcopic Biopsies in U.S. HIV Infected Women. Gagnon, S., Cohn, J., Spence, M., Harrison, D., Brinson, C., Stein, A., Hellinger, J., AmFAR's CBCTN, USA

Changes in Sexual Practices in a Cohort of HIV-Infected Women. Cohn, J., Gagnon, S., Spence, M., Harrison, D., Brinson, C., Stein, A., Hellinger, J., AmFAR's CBCTN, USA

Prevalence of Gynecologic Infections in a Cohort of HIV-Infected Women. Spence, M., Gagnon, S., Cohn, J., Harrison, D., Brinson, C., Stein, A., Hellinger, J., AmFAR's CBCTN USA

11th International Congress on Drug Therapy in HIV Infection - Poster Presentation
Long-term (96 and 144 Week) Efficacy and Safety From the VERxVE Trial Comparing Nevirapine Extended-Release (NVP XR) 400 mg Once a Day to Nevirapine Immediate-Release (NVP IR) 200 mg Twice a Day in Combination With Emtricitabine/Tenofovir in Treatment-Naïve HIV-1 Patients. Author: Cynthia Brinson, Johannes R. Bogner, Mark Nelson, Daniel Podzamczer, Anne Marie Quinson, Murray Drulak, and Joseph Gathe -**November 11-15, 2012;** Glasgow, UK

Published Articles:

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial-Jean-Michel Molina, Douglas Ward, Indira Brar, Anthony Mills, Hans-Jürgen Stellbrink, Luis López-Cortés, Peter Ruane, Daniel Podzamczer, Cynthia Brinson, Joseph Custodio, Hui Liu, Kristen Andreatta, Hal Martin, Andrew Cheng, Erin Quirk

The Lancet HIV Online,17 June 2018

A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain-PONE-D-17-20666R2- Deanna Kerrigan, Andrea Mantsios, Miguel Gorgolas, Maria-Luisa Montes, Federico Pulido, Cynthia Brinson, Jerome deVente, Gary J. Richmond, Sarah W. Beckham, Paige Hammond, David Margolis, Miranda Murray

05 Jan 2018 PLOS ONE

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials-D Hagins, C Orkin, ES Daar, A Mills, C Brinson, E DeJesus, FA Post, J Morales-Ramirez, M Thompson, O Osiyemi, B Rashbaum, H-J Stellbrink, C Martorell, H Liu, Y-P Liu, D Porter, SE Collins, D SenGupta1, M Das

HIV Medicine, 2018

A Preemptive Weapon

PrEP Treatment to Prevent HIV Promising if Physicians Can Identify High-Risk Minority Patients C.Brinson,M.D

Texas Medical Association-Public Health Feature — November 2016

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed- dose combinations containing emtricitabine as backbones for treatmet of HIV-1 infection in virologically suppressed adults: a randomized, double-blind, active-controlled phase 3 trial. Joel E.Gallant, Eric S. Daar, Francois Raffi, Cynthia Brinson, Peter Ruane, Edwin Dejesus, Margaret Johnson, Nathan Clumeck, Olayemi Osiyemi, Doug Ward, Javier Morales-Ramirez, Mingjin Yan, Michael E. Abram, Andrew Plummer, Andrew K Cheng, Martin S Rhee

The Lancet HIV Online, 14 March 2016

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomized controlled trial. Dr. Jacob P. Lalezari, Gulam H. Latiff, M.D., Cynthia C. Brinson, M.D., Juan Echevarria, M.D., Sandra Trevino-Perez, M.D., Prof. Johannes R. Bogner, M.D., Melanie Thompson, M.D., Jan Fourie, M.D., Otto A. Sussmann Pena, M.D., Fernando C. Mendo Urbina, M.D., Marcelo Martins, M.D., Iulian G. Diaconescu, M.D., David A. Stock, PhD, Samit R. Joshi, DO, George J.Hanna, M.D., Max Lataillade, DO

The Lancet HIV Online, 01 September 2015

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naïve adults with HIV-1 infection (LATTE): a randomized, phase 2b, dose-ranging trial. David A. Margolis, Cynthia C. Brinson, Graham H R Smith, Jerome de Vente, Debbie P Hagins, Joseph J Eron, Sandy K Griffith, Marty H St Clair, Marita C. Stevens, Peter E. Williams, Susan L Ford, Britt S Stancil, Melinda M Bomar, Krischan J Hudson, Kimberly Y Smith, William R Spreen.

Lancet Infectious Disease Online, 20 July 2015

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. F. Raffi, A. Rachlis, C. Brinson, K. Arasteh, M. Gorgolas, C. Brennan, K. Pappa, S. Almond, C. Granier, W. Nichols, R. Cuffe, J. Eron, S. Walmsley
AIDS, Volume 29, Issue 2 January 2015

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine In HIV-Infected Adults Previously Vaccinated with Pneumococcal Polysaccharide Vaccine. M. Glesby, W. Watson, C. Brinson, R. Greenberg, J. Lalezari, D. Skiest, V. Sundaraiyer, R. Natuk, A. Gurtman, D. Scott, E. Emini, W. Gruber, B. Schmoele-Thomas **The Journal of Infectious Diseases, November 2014**

Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens. A. Mills, C. Cohen, E. DeJesus, C. Brinson, S. Williams, K. Yale, S. Ramanathan, M. Wang, K. White, S. Chuck, A Cheng
HIV Clinical Trials Volume 14, Number 5 September/October 2013

Stribild, a Single Tablet Regimen for the Treatment of HIV Disease. C. Brinson
Combination Products in Therapy, March 26, 2013

VERxVE 144 week results: nevirapine extended-release (NVP XR) QD versus NVP immediate-release (IR) BID with FTC/TDF in treatment-naïve HIV-1 patients. C Brinson, J Bogner, M Nelson, D Podzamczer, A Quinson, M Drulak, J Gathe **Journal of the International AIDS Society,January 2012**

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1-Infected, Treatment-Experienced, CCR5 Antagonist-Naïve Subjects. Jacob Lalezari, M.D., Joseph Gathe, M.D., Cynthia Brinson, M.D., Melanie Thompson, M.D., Calvin Cohen, M.D., Edwin Dejesus, M.D., Jorge Galindez, M.D., Jerome A. Ernst, M.D., David E. Martin, PharmD, and Sandra M. Palleja, M.D.
JAIDS, Volume 57, Number 2, June 1,2011

Non-AIDS Related Research:

- **NCT02870101** Performance of Nucleic Acid Amplification Tests for the Detection of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* in Extragenital Sites (pNAAT) (2018)

- **NCT01846494** Longitudinal Assessment of Cardiovascular and Renal Health in Patients with Hepatitis-C (CARE-Hep C) (2017)

- **NCT02605174, Phase 3,** Col-Mig-302-A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A randomized, double-blind, placebo-controlled parallel group study (SPARTAN) (2017)

- **NCT02565186, PHASE 3** Col-Mig-305- An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR) (2017)

- **NCT02692716, Phase 3,** NN9924-4221-A Trial investigatingthe cardiovascular safety of oral semaglutide in subject's with type 2 diabetes (2017)

- **NCT02019264, Phase 4,** Eisai - APD356-G000-401: A Randomized, Double-blind, Placebo-controlled, Parallel-group Studyto Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of MajorAdverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors (2017)

- **NCT02822508, Phase 2/3,** BLI801-203-A Safety and Efficacy Evaluation of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation. (2016)

- **NCT02342249,** A **Phase 2b** Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX-787 Administered as Monotherapy and One Dose Level od VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicatged Seasonal influenza A in Adult Subjects (2016)

- **NCT02068963,** Collection of plasma and serum samples from individuals initiationg therapy with Sofosbuvir for chronic Hepatitis C virus infection for the clinical evaluation of the Aptima HCV Quant DX Assay (2016)

- **NCT02114151,** A **phase 3**, multicenter, open label, single arm study to investigate the efficacy and safety of a 12 week regimen of Simeprevir in combination with Sofosbuvir in treatment naïve or experienced subjects with chronic Genotype 1 Hepatitis C virus infection and Cirrhosis (2016)

- **NCT01457768,** A long term follow-up registry for subjects who did not achieve a sustained virologic response to treatment in Gilead sponsored trials in subjects with chronic Hepatitis infection (2016)

- **NCT02341664,** Patient and Provider Assessment of Lipid Management Registry (2015)

- **NCT01991795, Phase 3,** A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes (THEMIS – Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study) (2015)

- **NCT01962441**, A **phase 3B** randomized, open label, multi-center trial assessing Sofosbuvir + Ribavirin for 16 or 24 weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 weeks in subjects with Genotype 2 or 3 chronic HCV infection (2015)

- **NCT02451137, Phase 4** LPS14347:A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo® compared to commercially available basal insulins for initiation of therapy in insulin naïve patients with uncontrolled type 2 diabetes mellitus (2015)

- **NCT02526524, Phase 2,** LCRM112: A Randomized, double-blind, parallel-group, multicenter, placebo-controlled, dose-ranging study to evaluate the gylcemic effects, safety, and tolerability of metformin delayed-release in subjects with type 2 diabetes mellitus (2015)

- **NCT02122471, Phase 3,** Synergy SP304203-03: A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients with Chronic Idiopathic Constipation(2014)

- **NCT01965652, Phase 3,** Chronic Pain Receiving Opioid Therapy A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluatethe Long-term Safety of Naldemedine for the Treatmentof Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opiod Therapy (2014)

- Dose-finding of semaglutide administered subqutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes (2014)

- A trial comparing cardiovascular safety of insulin Degludec versus insulin Glargine in subject with type 2 diabetes at high risk of cardiovascular events (2014)

- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine with or without Metformin (2014)

- A phase III, randomized, double-blind and placebo-controlled study of once daily BI 201335 120mg for 24 weeks and BI 201335 340mg for 12 weeks in combination with pegylayed interferon-a and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C infection. BI 1220.47 (2014)

- A phase III, randomized, double-blind and placebo controlled study of once daily BI 201335, 240mg for 12 or 24 weeks in combination with pegylated interferon-a and ribavirin in patients with genotype 1 chronic hepatitis C infection who failed a prior PegINF/RBV treatment. BI 1220.7 (2014)

- A phase III, Randomised, partially double-blind and placebo-controlled study if BI 207127 in combination with Faldaprevir and Ribavirin in treatment-naïve patients with chronic Genotype 1b HCV infection. BI 1241.20 (2013)

- A targeted self-selection study for an Intranasal Allergy Relief product (2013)

- An Open Label Study to Evaluate the Contraceptive Efficacy and Safety of Norethindrone Acetate Transdermal Delivery System (2012)

- A multicenter, randomize, open-label, phase 2b study to evaluate the efficacy and safety if two regimens of all-oral triple therapy VX-222 in combination with Telaprevir [Incivek] and Ribavirin [Copegus]) in treatment-naïve subjects with genotype 1 chronic hepatitis C (2012)

- A twenty-four week randomized, double-blind, placebo-controlled, safety and efficacy trial of Flibanserin, with up-titration, 100 milligrams administered orally once daily in naturally postmenopausal women with hypoactive sexual desire disorder in North America. BI 511.156/BOUQUET (2011)

- A Phase II, Randomized, Double-blind, Multi-center, Placebo-controlled Study of the Safety and Efficacy of INH-08189 in Adjunctive Treatment with Peginterferon alfa-2a (Pegasys) and Ribavirin (Copegus) in Chronically-infected HCV Genotype 2 and 3 Treatment-naïve Subjetcs. INHIBITEX (2011)

- An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Regimens Containing PSI-352938, PSI-7977 and Ribavirin in Patients with Chronic HCV Infection. Quantum. (2011)

- A Multicenter, Open-Label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Oral Administration of PSI-7977 in Combination with Pegylated Interferon and Ribavirin in Treatment-Naive Patients with Chronic HCV Infection Genotype 1,4,5, or 6 (2011)

- MK 5172 PN003 A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 Hepatitis C Virus Infection (2011)

- A phase 3, randomized, active controlled, modified double-blind trial, evaluating the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared with a 23-valent pneumococcal polysaccharide vaccine (23Vps) in ambulatory elderly individuals aged 70 years and older who received 1 dose of 23Vps at least 5 years before study enrollment. (2011)

- A multicenter, randomized, open-label, phase 2b study to evaluate the efficacy and safety of two regimens of all oral triple therapy(VX-222 in combination with Telaprevir [Incivek] and Ribavirin [Copegus]) in treatment-naïve subjects with genotype 1a chronic Hepatitis C. (2011)

- A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NKTR-118 in patients with non-cancer related pain and opioid-induced constipation (OIC) with a 12 week extension. (2011)

- A phase 3, open label, single arm trial to evaluate the safety, tolerability, and immunogenicity of 3 doses of 13-valent pneumococcal conjugate vaccine in human immunodeficiency virus-injected subjects 18 years of age or older who have been previously immunized with the 23-valent pneumococcal polysaccharide vaccine. (2010)

- A phase 3, randomized, active controlled, modified double-blind trial, evaluating the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine when

administered over 12 months either as a 2-dose regimen or with 23-valent pneumococcal polysaccharide vaccine in healthy adults 60 to 64 years of age who are naïve to 23vPS. (2010)

- A 52-week efficacy and safety study to compare the effects of three dosage strengths of fluticasone furoate/GW64244 inhalation powder with GW6424444 on the annual rate of exacerbations in subjects with chronic obstructive pulmonary disease (COPD). (2010)

- A twenty-eight week, open-label, safety extension trial of flivaserin 100 mg daily in premenopausal and naturally postmenopausal women with hypoactive sexual desire disorder in North America. (2010)

- An open label study to evaluate the contraceptive efficacy and safety of Norethindrone Acetate transdermal delivery system. (2010)

- Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for12 or 24 weeks as combination therapy with pegylated interferon-alpha 2a and ribavirin (open label, randomized, Phase II). (2009)

- A Randomized, Double-Blind, Active-Controlled Parallel Group, Multicenter Study Comparing the Proportion of Subjects with Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either COREG CR + lisinopril or lisinipril Monotherapy (2008)

- A multi-centered, randomized, double-blind, placebo-controlled, parallel-group of sub-cutaneous MOA0728 for the treatment of opioid-induced constipation in patients with chronic non-malignant pain (2008)

- Randomized, double-blind, double-dummy trial of two sustained release formulations of Carisoprodol compared to placebo in patients with acute, painful musculoskeletal spasm of the lower back. (2008)

- A clinical outcomes study of Darapladib versus placebo in subjects with chronic coronary heart disease to compare the incidence of major adverse cardiovascular events (MACE). The stabilization of atherosclerotic plaque by initiation of Darapladib therapy. (2008)

- A phase III, randomized, double-blind, placebo-controlled, multi-centered study of the long-term safety and efficacy of LibiGel for the treatment of hypoactive sexual desire disorder in postmenopausal women. (2008)

- Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 24 weeks as combination therapy with pegylated interferon-alpha 2a and ribavirin (double-blinded, randomized, placebo controlled, Phase II). (2008)

- Safety, antiviral activity, and pharmacokinetics of multiple rising oral doses of BI 201335 NA as oral solution in treatment-naïve patients with chronic hepatitis C infection for 14 days monotherapy followed by combination with Pegylated Interferon and Ribovarin for an additional 14 days (double blind, placebo controlled); and in treatment-experienced patients with chronic hepatitis C infection for 28 days as combination therapy with Pegylated Interferon and Ribovarin (open-label) (2007)

- A study to evaluate the persistence of the antibody response elicited by 13-vanent Pneumococcal Conjugate vaccine (13vPnC) in healthy adults who have previously been vaccinated with either 2 doses of 13vPnC or 13vPnC and 23-valent Pneumococcal polysaccharide vaccine in different sequential order. (2007)

- A randomized, double-blind, double-dummy, parallel group, factorial design trial to assess the efficacy and safety of up to six weeks treatment with 20 mg, 40 mg, 80 mg qd doses of Carvdilol Controlled Release formulation (Coreg CR) or 10 mg, 20 mg, 40 mg qd doses of Lisinorpil (Zestril) or a combination of one of the doses of each medication. (2007)

- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Adaptive Design Study of 4 Fixed Oral Doses of DVS-233 SR in Adult Outpatients with Painful Diabetic Peripheral Neuropathy (2006)

- A 24 week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Safety And Efficacy Of PPM-204 In Subjects With Type 2 Diabetes (2006)

- A Randomized, Double Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment With 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40mg QD Doses of Lisinopril (Zestril) or a Combination of One of the Doses of Each Medication (2006)

- A multi-center, Randomized, open-label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with Vildagliptin 100mg, qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community-based practice setting (2006)

- A Multicenter, Randomized, Double-Blind rial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (2005)

- A multicenter, randomized double-blind factorial study of the co-administration of MK-0431 and Metformin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control. (2005)

- A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of MK-0364 in Obese Patients (2005)

- A Multicenter, Randomized, Double-Blind Study of MK-0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (2004)

- A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431 Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control (2004)

- Evaluation of the Safety and Tolerability of a High Potency Dose of Varicella Zoster Virus Vaccine Live Among Adults 50 Years of Age and Older (2004)

- A Multicenter, Randomized, Double Blind, Active- and Placebo Controlled, Phase III, Efficacy and Safety Study of Oxycodone HCl and Low-Dose Naltrexone HCl in Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee (2004)

- A Multi-Center, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment With LAF237 50mg BID to Rosiglitazone 8mg QD in Drug Naïve Patients with Type 2 Diabetes (2004)

- A Phase III, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of StaphVAX, a Bivalent *Staphylococcus aureus* Glycocongugate Vaccine in Adults on Hemodialysis (2004)

- Randomized, Controlled, Open-Label, Multi-center, Parallel-Group Study to Demonstrate the Efficacy and Safety of RO0503821 when Administered Intravenously for the Maintenance Treatment of Anemia in Patients with Chronic Kidney Disease who are on Dialysis. (2004)

- A Randomized, Open-Label, Parallel-Design Trial to Assess the Safety of Glucose Control as Measured by the Frequency of Severe Hypoglycemia Events using Dosing Algorithms Based On Different Fasting Blood Glucose Goals with Lantis In Adult Individuals With Type II Diabetes Who Have not Achieved The Target A1c Goal of < 7% with Oral Hypoglycemia Agents. (2004)

- A phase I dose-ranging study of the safety, tolerability, and immunogenicity of the Merck trivalent adenovirus serotype 5 HIV-1 gag/pol/nef vaccine (MRKAd5 HIV-1gag/pol/nef) in a prime –boost regimen in healthy adults. (2003)

- A Randomized, Open-Label Clinical Evaluation or PROCRIT (Epoetin alfa) for MaintenancePhase Treatment of Patents with Anemia due to Chronic Kidney Disease (2003)

- A Multicenter, Randomized, Double-Blind, Placebo controlled, Phase II trial to evaluate the safety and efficacy of BMS-477118 as mono-therapy in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control (2003)

- A Multicenter, Placebo Run-In, Randomized, Double-Blind, Parallel Group Trial to Evaluate the Effects of Eplerinone vs. Eplerinone/Lisinopril in Patients with Renal Insufficiency (2003)

- A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-0767 Added to Insulin in Patients With Inadequately Controlled Type 2 Diabetes Mellitus (2003)

- A Multicenter, Double-Blind, Randomized, Placebo- and Active- Controlled Dose-Range Finding Study of L-000224715 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (2003)

- A Phase I Dose-Ranging Study of the Safety, Tolerability, and Immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd5 HIV-1 gag/pol/nef) in a Prime-Boost Regimen in Healthy Adults (2003)

- A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of 12 Weeks Oral Treatment with ACH 126,443 (β-L-Fd4C) in Adults with Lamivudine-Resistant Chronic Hepatitis B (2003)

- A Probe Study of the Safety, Tolerability, and Immunogenicity of a Three-Dose Regimen of the Ad5 Human Immunodeficiency Virus (HIV-1) gag Vaccine (Adenovirus Serotype 5 HIV-1 gag Vector) in Healthy Adults (2002)

- Impact of Point-of-Care vs. Laboratory Testing of Hemoglobin A1c (HbA1c), and Intense vs. Standard Monitoring of Titration Algorithm Adherence on Glycemic Control in Type 2 Diabetes Subjects, Who are Inadequately Controlled on Oral Anti-Hyperglycemic Therapy, And Starting Lantus (Insulin Glargine Injection): A 2x2, Randomized, Open-Label Trial. (2002)

- Study of the Safety, Tolerability, and Immunogenicity of HIV-1 gag DNA Formulated With CRL1005 Adjuvant Followed by the Adenovirus Serotype 5 HIV-1 gag Vaccine (Ad5 HIV-1 gag) in a Prime / Boost Regimen. (2002)

- Maintenance Use Protocol for L2-7001 (Recombiant Human Interleukin-2) in Subjects Infected with HIV who have successfully completed the Chiron Sponsored L2-7001 trial CS-MM-9901. (2001)

- A Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Recombinant Human Growth Hormone (Serostim) in the Treatment of HIV-Associated Catabolism / Wasting. (2001)

- Identification of Migraine Headache Among Self-Described and / or Physician Diagnosed Sinus Headache Sufferers and Treatment with Imitrex 50mg Tablets. Protocol #SUM40294 (summit trial) (2001)

- A Double – Blind Comparison of 80mg and 160mg Doses of Pravastatin with Placebo in Hypercholesterolemic Subjects. (2000)

- A Randomized, Open label, multicenter, Phase lll Study Evaluating the Efficacy and Safety of Peginterferon alfa-2a (RO 25-8310) in Combination with Ribavirin (RO 20-9963) given 24 weeks

versus 48 weeks versus no treatment in Patients with Chronic Hepatitis C and persistently normal ALT levels. (2000)

- A Double – Blind Comparison of 80mg and 160mg Doses of Pravastatin with Placebo in Hypercholesterolemic Subjects. (2000)

- Omapratrilat Cardiovascular Treatment Assessment versus Enalapril (Octave) (2000)

AIDS Related Research:

- GS-US-382-3961: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers (2018)

- GS-US-382-1450-A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults(2018)

- GS-US-380-4580: A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects (2018)

- Performance Evaluation: "Elecsys® HIV Duo on the cobas e 801 Immunoassay Analyzer" Sample Collection (2018)

- TMC114IFD3013: A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus type 1 (HIV-1) infected subjects (2018)

- GS-US-412-2055-A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection (2018)

- GS-US-380-1489-Phase 3 Results for Investigational Fixed-Dose Combination of B/F/TAF for Treatment of HIV-1 Infection in Treatment-Naïve Adults (2018)

- GS-US-380-1490: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults (2018)

- GS-US-380-1878-A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy

of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (2018)

- GS-US-380-1844-A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed (2018)

- GS-US-311-1717-A Phase IIIb, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC (2018)

- SB-728-1101- A Phase I, Open-Label Study to Assess the Effects of Escalating Doses of Cyclophosphamide on the Engraftment of SB-728-T in Aviremic HIV-Infected Subject's on HAART (2018)

- GSK-201637-A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI Based Antiretroviral Regimen in HIV-1-Infected Adults Who Are Virologically Suppressed (2017)

- SB-728-1401-A Phase ½ , Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning (2017)

- ATLAS-2M-207966- A study to compare a regimen of two drugs (called Cabotegravir and Rilpivirine) administered every 8 weeks (every 2 months) or every 4 weeks (monthly) (2017)

- GSK 205543-A Phase III, randomised, double-blind, multicentre, parallel- group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults (2017)

- GS-US-141-1475 - A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults (2017)

- GS-US-202-0111-A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Positive, Antiretroviral Treatment- Naïve Adults (2017)

- GS-US-292-0104-A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment - Naive Adult (2017)

- GSK-204862-A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who are virologically suppressed (2017)

- GS-US-292-1823-A Phase 3b, Randomized, Open-Label Study to Evaluate the Benefit of Switching from Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) plus a Third Agent to the Elvitegravir /Cobicistat /Emtricitabine /Tenofovir alafenamide (E/C/F/TAF) Fixed-Dose Combination in Virologically-Suppressed HIV-Infected Adult Patients (2017)

- GS-US-366-1216-A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF (2016)

- GS-US-366-1160-A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects (2016)

- A phase 2b, randomized, active-controlled, staged, open-label trial to investigate safety and efficacy of BMS-955176 in combination with dolutegravir and atazanavir (with or without ritonavir) in treatment-experienced HIV-1 infected adults (2016)

- A phase 3 randomized, double-blind study to evaluate the safety and efficacy of Elvitegravir/Cobicistat/Emtricitibine/Tenofovir Alafenamide versus Elvitegravir/Cobicistat/Emtricitibine/Tenofovir Disoproxil Fumarate in HIV-1 positive, antiretroviral treatment-naïve adults. (2016)

- Atlas-201585-Study Evaluating the Efficacy, Safety, and Tolerability of Switching to long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1 Infected Adults (2016)

- GS-US-292-1249: A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults (2016)

- GS-US-236-0123: A Phase 3B Open-Label Pilot study to Evaluate Switching from a Regimen Consisting of Raltegravir plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients (2016)

- AI438011 - A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-label Period on the Recommended Dose (2016)

- GS-US-311-1089/IND No:111,851: A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV 1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF (2016)

- GS-US-216-0130: A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV-1 Infected, Antiretroviral Treatment-Naïve and –Experienced Adults with No Darunavir Resistance-associated Mutations (2015)

- GS-US-183-0145 A Multicenter, Randomized, Double-Blind, Double-Dummy,Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults (2015)

- A Randomized, Double-blind Phase 3B Study to Evaluate theSafety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DisoproxilFumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1Infected, Antiretroviral Treatment-Naïve Women (2015)

- A GSK1349572 dolutegravir open label protocol for HIV infected, adult and adolescent patients with integrase resistance: expanded access program. GSK (2014)

- A Phase III study to demonstrate the antiviral activity and safety of GSK1349572 in HIV-I infected adult subjects with treatment failure on an integrase inhibitor containing regimen. GSK. (2013)

- A Phase IIB randomized, controlled, partially blinded clinical trial to investigate safety, efficacy and dose-response of BMS-986001 in treatment-naïve HIV-1-infected subjects, followed by an open-label period on the recommended dose. BMS (2013)

- A Phase 3B, randomized, open-label study to evaluate the safety and efficacy of a single tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate compared with a single tablet regimen of efavirenz/emtricitabine/tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naïve adults. Gilead (2013)

- A 12 week, randomized, double-Blind, active-Controlled, parallel-group study comparing pitavastatin 4mg vs. pravastatin 40mg in HIV-infected subjects with dyslipidemia, followed by a 40-week safety extension study. KOWA (2013)

- A Multicenter, Open-label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination with Pegylated Interferon and Ribavirin in Treatment-Naïve Patients with Chronic HCV Infection Genotype 1, 4, 5, or 6 The ATOMIC Study: (2012)

- A phase III, randomized, double-blind and placebo-controlled study of once daily BI 201335 120mg for 24 weeks and BI 201335 340mg for 12 weeks in combination with pegylaye interferon-a and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C infection. (2012)

- A Phase III Study to demonstrate the antiviral activity and safety of Dolutegravir in HIV-1 infected adult subjects with treatment failure on an Integrase inhibitor containing regimen. (2011)

- A phase 2b open-label pilot study to evaluate switching from a regimen consisting of a efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single tablet regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (EFV/RPV/TDF) (STR) in virologically-suppressed, HIV-1 infected subjects. (2011)

- A Phase III randomized, double-blind study to demonstrate the antiviral activity of Dolutegravir (DTG)50mg twice daily versus placebo both co-administered with failing antiretroviral regimen over seven days, followed by an open label phase with all subjects receiving DTG 50mg twice daily co-administered with an optimized background regimen (OBR) in HIV-1 infected, Integrase inhibitor therapy experienced and resistant adults. (2011)

- A multicenter, randomized, double-blind, comparative trial of Maraviroc+Darunavir/Ritonavir versus Emtricitabine/Tenofovir+Darunavir/Ritonavir for the treatment of antiretroviral-naïve infected patients with CCR5-Tropic HIV-1. (2011)

- A phase IIb, dose ranging study of oral GSK 1265744 in combination with nucleoside reverse transcriptase inhibitors for induction of HIV-1 virologic suppression followed by an evaluation of maintenance of virologic suppression when oral GSK 1265744 is combined with oral rilpivirine in HIV-1 infected, antiretroviral therapy naïve adult subjects. (2011)

- A phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with no non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. (2010)

- A phase III, randomized, double blind study of the safety and efficacy of GSK1349572, 50 mg once daily or Raltegravir 400 mg twice daily, both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects. (2010)

- A multicenter, single arm, open-label, study of the once daily combination of Etravirine and Darunavir/Ritonavir as dual-therapy in early treatment of experienced patients. (2010)

- A proof of concept, multiple, dose-escalating study to evaluate the antiviral activity, safety, and pharmacokinetics of the CCR5 antagonist TAK-652 in HIV-1 infected, antiretroviral treatment-experienced CCR5 antagonist-naïve patients. (2009)

- A multicenter, randomized, double-blind, double- dummy, phase 3 study of the safety and efficacy of Ritonavir-boosted Elvitegravir (EVG/r) versus Raltegravir (RAL) each administered with background regimen in HIV-1 infected patients, antiretroviral treatment-experienced adults. (2009)

- A phase 2b, randomizes, double-blind, 48-week, multicenter, dose-response study of Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with HIV-1. (2009)

- An open label, randomized parallel group study to assess the efficacy and safety of switching HIV-1 infected patients successfully treated with a Nevirapine IR based regime to Nevirapine XR or a remaining on a Nevirapine IR based regime. (2009)

- A study of the safety tolerability and pharmacokinetics of KD-247, a humanized monoclonal antibody that recognizes the principal neutralizing determinant of HIV-1, in asymptomatic HIV-1 seropositive individuals who are not receiving concurrent antiretroviral therapy. (2008)

- A prospective, randomized, open label phase IV study to evaluate the rationale of switching from fixed dose Abacavir (ABC)/Lamivudine (3TC) to fixed dose Tenofovir DF (TDF)/Emtricitabine (FTC) in virologically suppressed, HIV-1 infected patients maintained on a Ritonavir boosted inhibitor containing antiretroviral regimen. (2008)

- A Phase III, randomized, double blind trial of TMC278 75 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral naïve HIV-1 infected subjects (2008)

- A multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA in HIV-Infected Patients, Switched from a Stable KALETRA-Based Regimen (2008)

- A randomized, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg qd Nevirapine extended release formulation in comparison to 200 mg bid Nevirapine immediate release in combination with Truvada in antiretroviral therapy naïve HIV-1 infected patients. (2007)

- Randomized, double-blind, parallel-group, placebo controlled, two-stage study to assess the efficacy and safety of Crofelemer 125 mg, 250 mg, and 500 mg orally twice daily for the treatment of HIV associated diarrhea. (2007)

- A randomized, double blind controlled study on the effect of one year administration of a nutritional concept on immunological status in HIV-1 positive adults not on antiretroviral therapy. (2007)

- Study Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonovir + the Abacavir/Lanivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an additional 48 weeks in Antiretroviral-Naïve HIV-1 Infected HLA-B*5701 Negative Subjects (2007)

- A randomized, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400mg QD nevirapine extended release formulation in comparison to 200mg BID nevirapine immediate release in combination with Truvada in antiretroviral naïve HIV-1 infected patients (2007)

- A phase II dose-escalating, placebo-controlled, double-blind, parallel group study in HIV treatment-experienced patients to evaluate the safety, tolerability and efficacy of PA103001-04 administered as functional monotherapy for 14 days and as part of an optimized background regimen for an additional 10 weeks (2007)

- An open-label, multicenter trial to compare the efficacy, safety, and tolerability of PREZISTA by Gender and Race, when administered in combination with an individually optimized background regimen over a 48 week treatment period (2007)

- Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500mg/200mg BID in antiretroviral treatment experienced HIV-positive patients with HCV or HBV co-infection, with a pilot evaluation of therapeutic drug monitoring (TDM). An open-label, multicenter, multinational trial with randomization to standard of care (SOC) or TDM (2007)

- Safety, efficacy and pharmacokinetics of tipranovir boosted with low dose ritonavir (TPV/r) 500mg/200mg BID in a racially and gender diverse HIV-positive treatment experienced population with a pilot evaluation of therapeutic drug monitoring (TDM). An open-label, multicenter, multinational trial with randomization to standard of care (SOC) or TDM TPV/r therapy (2007)

- A Randomized, Double-blind, Controlled Study on the Effect of One Year Administration of a Nutritional Concept on Immunological Status in HIV-1 Positive Adults not on Antiretroviral Therapy (2007)

- A multicenter, randomized, double-blind, placebo-controlled trial of a novel CCR5 antagonist, in combination with optimized background therapy versus optimized background therapy alone for the treatment of antiretroviral experienced HIV-1 infected subjects. (2006)

- A retrospective case-control study to estimate the sensitivity and specificity of a pharmacogenetic marker (HLA-B*5701) in subjects with and without sensitivity to abacavir (2006)

- A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies (2006)

- A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naïve HIV-Infected Patients, Each in Combination with Truvada (2006)

- A Phase II, Randomized, Blinded, 12-week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir Versus Lamivudine in Combination with Efavirenz and Tenofovir in HIV-1 infected, Treatment Naïve Subjects, with a 12 Week Extension Treatment Period (2006)

- An open-label trial with TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 and TMC125-C216) (2006)

- An open-label, multicenter trial to compare the efficacy, safety, and tolerability of PREZISTA/r by Gender and Race, when administered in combination with an individually optimized background regimen over a 48 week treatment period (2006)

- A phase II dose-escalating, placebo-controlled, double-blind, parallel group study in HIV treatment-experienced patients to evaluate the safety, tolerability and efficacy of PA103001-04 administered as functional monotherapy for 14 days and as part of an optimized background regimen for an additional 10 weeks (2006)

- A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of PEGASYS 180 ug plus Copegus 1000 (<75kg) or 1200 mg (>=75kg) to the Currently Approved Combination of PEGASYS 180 ug plus Copegus 800 mg in Interferon-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection Co-infected with Human Immunodeficiency Virus (HIV-1) (2006)

- A Phase 1 Multicenter, Randomized, Double-Blind, Adjuvant-Controlled Trial to Evaluate the Safety and Immunogenicity of an HIV CTL Multi-Epitope Peptide Vaccine formulated with RC529-SE and GM-CSF Given to HIV-1 Positive Adults Receiving Stable HAART (2005)

- A multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of a 2 mg dose of TH9507, a growth hormone releasing factor analogue, in HIV patients with excess of abdominal fat accumulation. (2005)

- A phase 1 multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of an HIV-1 gag DNA vaccine administered alone or with escalating doses of IL-12 DNA or IL-15 DNA molecular adjuvants to HIV-1 positive adults receiving stable HAART (2005)

- Viriviroc (SCH 417690) in Combination Treatment with Optimized ART Regimen (2005)

- A Phase III Randomized, Double-Blind, Placebo-Controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 subjects with limited to no treatment options (2005)

- A Randomized, Open Label Study Assessing the Efficacy of Initiating PROCRIT Dosing at Q2W .vs. PROCRIT Dosing at QW in Anemic HIV Subjects (2005)

- A Multi-center, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in combination with Optimized Background Therapy versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects (2005)

- A 96 Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Combination with Kaletra in Antiretroviral-Naïve HIV-1 Infected Subjects (2005)

- A Phase IIIb/IV Randomized, controlled study evaluating an intensification treatment strategy of adding Enfuvirtide(ENF) to an oral Highly AntiRetroviral Therapy (HAART) in treatment experienced patients (2005)

- A Multicenter, Double-Blind, Randomized, Placebo-Controlled study assessing the efficacy and safety of a 2mg dose of TH9507, a Growth Hormone-Releasing Factor analogue, in HIV patients with excess of abdominal fat accumulation (2005)

- A Randomized, Controlled, Open-Label Trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/TRV in treatment experienced HIV-1 infected subjects (2005)

- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Trial of Pregabalin versus Placebo in the Treatment of Neuropathic Pain associated with HIV Neuropathy (2005)

- Randomized Trial Comparing the Efficacy and Safety of RTV-Boosted Lexiva with Truvada Versus RTV-Boosted Rayataz with Truvada in Antiretroviral-Naïve Patients Over 48 Weeks (2005)

- A Randomized, Double-Blind, Placebo-Controlled multicenter dose ranging study to evaluate the efficacy and safety of prosaptide over six weeks of treatment for the relief of neuropathic pain associated with HIV-1 (2005)

- A Phase I, Multicenter, Randomized, Double-Blind Adjuvant-Controlled Trial to Evaluate the Safety and Immunogenicity of an HIV CTL Multi-Epitope Peptide Vaccine formulated with RC529-SE 50 and GM-CSF 250 Given to HIV-1 Positive Adults Receiving Stable HAART (2005)

- A placebo-controlled, double blind, parallel dose group study exploring the safety, tolerability and virological effect of 50, 100, and 200 mg Reverset in HIV infected antiretroviral therapy experienced subjects when used in combination with other antiretroviral agents (2004)

- A Phase II Open-Label, Randomized, Active-Controlled Study Comparing the Efficacy and Safety of new Once Daily Enfuvirtide Dosing Versus the Currently Recommended Twice Daily Dosing in HIV-1 Infected Treatment-Experienced Patients. (2004)

- A Phase III Multi-center, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of Serostim (Mammilian Cell-Derived Recombinant Human Growth Hormone r-hGH) in the Treatment and Maintenance of Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) (2004)

- A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of TRIZIVIR (Abacavir 300mg, Lamivudine 150mg, and Zidovudine 300mg) BID vs Combivir (Lamivudine 150mg and Zidovudine 300mg) BID plus Atazanavir 400mg QD in Antiretroviral Naïve HIV-1 Infected Subjects over 48 Weeks (2004)

- A randomized, double-blind, controlled dose finding study of NGX-4010 for the treatment of painful HIV-Associated distal symmetrical polyneuropathy (2004)

- A Phase IIIB, Open Label, Randomized Study Evaluating the Safety and Antiretroviral Efficacy of Nucleoside Reverse Transcriptase Inhibitor Sparing Regimens Containing Atazanavir, Ritonavir and Efavirenz Once Daily, in the Treatment of Antiretroviral Naïve HIV-1 Infected Adults (2004)

- A Single-Blind, Randomized, Multi-Center Study of the Efficacy and Safety of a Clotrimazol Buccal Tablet (10mg) Administered Once a Day Mycelex Troche (50mg) Administered Five Times a Day (10mg per dose) for the Treatment of Oropharyngeal Candidiasis (2004)

- A randomized, double-blind, placebo-controlled, multicenter, dose ranging study to evaluate the efficacy and safety of prosaptide over 6 weeks of treatment for the relief of neuropathic pain associated with HIV-1 (2003)

- A Phase IIIB, Open-Label, Randomized, 96-Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir versus Atazanavir/Ritonavir, each in Combination with Tenofovir and either Didanosine EC or Stavudine XR in HIV-11 Infected Subjects Receiving a NNRTI-Containing HAART Regiment who are Experiencing Their First Virologic Failure (2003)

- A Phase IIIB, Open-Label, Randomized, Multicenter Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir/Ritonavir in HIV-1 Infected Subjects Who Have Achieved Virologic Suppression on a Lopinavir/Ritonavir Based Regimen (2003)

- Vest-QD: A Phase IV, Open-Label, Randomized, Multicenter Study Switching HIV-1 Infected Subjects With a Viral Load <50 Copies/ML On A First PI-Based Regimen to an Efavirenz Substitution Regimen (2003)

- A Phase II, Randomized, Double-Blind, Dose-Ranging Study of Capravirine (AG1549) in Combination with Kaletra and at least Two Nucleoside Reverse Transcriptase Inhibitors in HIV-

Infected Subjects Who Failed Antiretroviral Regimens Containing Protease Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Nucleoside Reverse Transcriptase Inhibitors (2003)

- A Randomized, Open-Label Study of 800 mg Lopinavir/200 mg Ritonavir QD in Comination with Tenofivir and Emtricitabine vs. 400 mg Lopinavir/100mg Ritonavir BID in Combination with Tenofivir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects (2002)

- A Double-Blind, Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen (2002)

- A Rollover T20 Administered in Combination with a Background Antiviral Regimen in HIV-1 Positive Adults Who Are Participating in a Phase II Clinical Trial of T-20. (2002)

- A Phase III, Randomized, Multicenter, Parallel Group, Open-Label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908 / Ritonavir (700mg / 100mg Twice Daily or 1400mg / 200mg Once Daily) for 48 Weeks in Protease Inhibitor Experienced HIV-Infected Adults Experiencing Virological Failure. (2001)

- A Randomized, Phase IV Study to Evaluate the Quality of Life of Subjects Infected with HIV-1 and who are Intolerant to Their Current Antiretroviral Therapy and Alter Therapy to Kaletra (M00-267, PLATO) (2001)

- A Retrospective, Case-Control Study to Investigate Genetic Polymorphisms in HIV Infected Subjects who Developed Hypersensitivity Following Treatment with Abacivir. (2001)

- A trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV – 1 Positive Subjects (2001)

- A Randomized, Partially – Blinded, Multicenter, Phase II, Study Investigating the Efficacy and Safety of Peginterferon alfa – 2a (RO 25 – 8310) and Peginterferon alfa – 2a with Ribavirin (RO 20 –9963) in Treatment Naïve Patients with Chronic Hepatitis C, Coinfected with Human Immunodeficiency Virus (2000)

- A Phase II, Randomized, Open Label Comparative, Pilot Study of two Different dosage Regimens of Ampenavir (900 BID vs. 600mg BID) in Combination with Ritonavir (100mg BID) plus

- Abacavir, Another NRTI, and Either Efavirenz or Tenofovir DF in HIV – 1 Infected Subjects with Virologic Evidence of Treatment Failure (2000)

- A Bridging Dose – Escalation study of the safety, pharmacokinetic properties, and Immunologic effect of the Subcutaneous L2-7001 (Recombinant Human Interleukin – 2) in Patients Infected

with HIV with CD4 + T cell counts of 300 to 500 cells/mm and Viral Load < 10,00 copies/mL, on Active Antiretroviral Therapy (ART). Protocol CS-MM-9901 (2000)

- A Randomized, Double blind, Equivalence Trial Comparing Emtricitabine to Stavudine within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral - Drug Naïve HIV –1 Infected Patients (2000)

- A Phase II, Single – blind, Randomized, Placebo-controlled Study of Capravirine (AG1549) in Combination with VIRACEPT™ and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects who failed an initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen (2000)

- A Randomized, Double –Blind, Adjuvant- Controlled, Multicenter, Phase III Study to Compare the Virologic and Immunologic Effect of Highly Active Antiretroviral Therapy (HAART) Plus Incomplete Freund's Adjuvant (IFA) in Antiretroviral- Naïve Patients Infected With Human Immunodeficiency Virus Type 1 (HIV-1) (2000)

- A Controlled Phase II Trial Assessing Three Doses of T-20 in Combination with Abacavir and Efavirenz in HIV –1 Infected Adults (2000)

- To Evaluate Safety and Efficacy of Adefovir Dipivoxil as Intensification Therapy in Combination with HAART in Patients with HIV Viral Loads ≥ 50 and ≤ 400 (1999)

- To Evaluate the Safety and Antiviral Efficacy of a Novel HIV – Protease Inhibitor, in Combination with D4T and 3TC as Compares to a Reference Combination Regimen (1999)

- A Noncomparative, Multisite, Open Label, 48 week study to Monitor the Safety and Tolerability of MK-0639 (Indinavir Sulfate) 800mg q8h. Administered as Monotherapy or in Combination with Reverse Transcriptase Inhibitor Therapy for the treatment of HIV –1 Infection in Advanced AIDS Patients (CD4 Counts ≤ 50 cells/mm3) (1999)

- A Randomized, Double -Blind, Phase III Study of ABT-378 / Ritonavir Plus Stavudine and Lamivudine vs. Nelfinavir and Lamivudine in Antiretroviral-Naïve HIV-Infected Subjects (1999)

- A Randomized, Open-Label Equivalence Study of FTC Versus Lamivudine in Patients on a Stable Triple Antiretroviral Therapy Regimen Containing Lamivudine, Stavudine or Zidovudine, and a Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor, Protocol FTC-303 (1999)

- An Open Label Protocol for Subjects with HIV-1 Infection who have Experience Treatment Failure or are Intolerant to Previous Inhibitor Therapy (1998)

- An Open Label Study of the Effect of Thalidomide on Body Composition in Adults With HIV-Associated Wasting (1998)

- Chiron Study – CS-GT005-Extended Safety Evaluation in Subjects Who Have Participated in Chiron Technologies Center for Gene Therapy Retrovirus Protocols (1998)

- Protocol Number: ATO-R07 "A Randomized Open Label Multicenter Crossover Study to Observe Subject Preference for Two Package Forms of Mepron® Suspension (1998)

- PREVEON™ (adefovir dipivoxil, GS840) Expanded Access Program. (1998)

- An open-label, non-randomized trial to evaluate the tolerability and safety of VIRAMUNE® (nevirapine) in adult and pediatric patients with progressive, symptomatic HIV disease (VIRAMUNE® expanded access program) (1997)

- Chiron Study CS-GT003: A Phase II, Randomized, Double Blind Placebo Controlled Study of Combination Drug Antiretroviral Therapy to Include a Reverse Transcriptase Inhibitor and a Protease Inhibitor Plus HIV-IT (V) or Placebo in HIV Patients with CD4 Counts $\geq$ 100, and HIV RNA $\geq$ 1,000, but $\leq$ 10,000 (1997)

- "An Open-Label, Randomized, Comparative Study of Zerit® + Epivir™ + Crixivan® versus Retrovir® + Epivir™ + Crixivan® in HIV-Infected, Antiretroviral Naive Subjects with CD4 cell counts of 200-700/mm3 and HIV RNA Baseline Copy Number of $\geq$ 10,000 Copies/ml (1996)

- "A Phase III Randomized, Double-Blind, Placebo Controlled Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rhu- GM-CSF) in Patients with Advanced HIV Disease Protocol 001.0012 (1996)

- ""Viracept™ Expanded Access Program" (1996)

- "The Effect of PROCRIT on the Quality of Life of HIV-Infected Patients" (1996)

- "Delavirdine Mesylate Expanded Access Program for HIV-1 Infected Patients" (1996)

- Study 806: "A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 40 Units of HIV-1 Immunogen, 10 Units of HIV-1 Immunogen, and IFA Alone Every Three Months on AIDS Free Survival in Subjects with HIV Infection and CD4 Lymphocytes Between 300 and 549 Cells/*m*l Regardless of Concomitant HIV Therapies." (1995)

- ALZA Corporation, Protocol Number C-95-013 "An Open-Label, ContinuationStudy of Testoderm® Testosterone Transdermal System (CIII) in Hypogonadal Males with HIV-Related Wasting" (1995)

- ALZA Corporation, Protocol Number C-95-012; "A Placebo-Controlled Evaluation of the Effect of Chronic Testosterone Replacement Therapy (Testoderm®TestosteroneTransdermal System) on Body Cell Mass and Body Weight in Hypogonadal Males with AIDS" (1995)

- An Open Label International Compassionate Treatment Program for the use of Saquinavir (Ro 31-8959; HIV Proteinase Inhibitor) Either as Monotherapy or in Combination with other Anti-Retroviral Drugs in Patients with Proven HIV Infection (1995)

- "A Phase III Comparative Trial of ABT-538 Alone, Zidovudine Alone or the Combination of ABT-538 and Zidovudine in HIV-Infected Patients Without Prior Antiretroviral Therapy" (1995)

- "An Open-Label, Multicenter Study to Provide Expanded Access to and to Obtain Additional Safety Data on Serostim™ (Mammalian Cell-Derived Recombinant Human Growth Hormone, r-hGH[m]) in the Treatment of Adults with Advanced AIDS Wasting (1995)

- Vistide™ (Cidofovir Intravenous) Treatment IND Protocol for Relapsing Cytomegalovirus Retinitis in Patient with AIDS (1994)

- A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/ Ethambutol Regimen Containing Rifabutin (450 mg/day) or Rifabutin (300 mg/day) or Placebo (1993)

- A Multi-Center Double-Blind Parallel Study to Compare the Safety and Efficacy of 300 mg AZTEC, given twice daily, to 200 mg of Retrovir, given three times daily in patients who are HIV positive (1993)

- A Randomized, Double-Blind Multicenter Trial to Compare the safety and efficacy of 3TC monotherapy versus zidovudine (AZT) monotherapy versus 3TC administered concurrently with AZT in the treatment of HIV-1 infected patients who are AZT Naive ($\leq$ 4 weeks) with CD4 cell counts of 200-500/mm3 (1993)

- A Randomized 3TC, ddC Double-Blind (AZT Open-Labeled) Multicenter Trial to Evaluate the safety and efficacy of 3TC (low dose) administered concurrently with zidovudine (AZT) versus 3TC (high

- dose) administered concurrently with AZT versus ddC Administered concurrently with AZT in the Treatment of HIV-1 Infected AZT-Experienced ($\geq$ 24 weeks) patients with CD4 Cell Counts of 100-300/mm3 (1993)

- Double-Blind Study of Thymopentin in Asymptomatic, HIV-Infected Patients receiving either mono (AZT or ddI) or combination (AZT/ddI or AZT/ddC) antiretroviral therapy with CD4 cell count of 100-400/mm3 (1993)

- A Randomized Dose Response Study of Three-fixed doses of Delavirdine (U-90152S) in Combination with Zidovudine (ZDV) versus ZDV alone in HIV-1 Infected Individuals with a CD4 count of 200-500/mm3 (1993)

- A Randomized Comparative Trial of Delavirdine in Combination with Didanosine (ddI) versus ddI alone in HIV-1 Infected Individuals with a CD4 count of $\leq$300/mm3 (1993)

- Optional, Open-Label, Extended Use Delavirdine Mesylate Treatment in Triple Combination for HIV-1+ Patients Who Participated in Other Delavirdine Mesylate Protocols (1993)

- Study of Cervical Disease in HIV Infected Women Comparing q 6 month Pap Smear vs. Pap Smear and Yearly Colposcopy/Biopsy (1992)